Dakota Wealth Management Lowers Stock Position in Johnson & Johnson $JNJ

Dakota Wealth Management trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 104,090 shares of the company’s stock after selling 8,111 shares during the quarter. Dakota Wealth Management’s holdings in Johnson & Johnson were worth $19,300,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of JNJ. Clark Asset Management LLC boosted its position in shares of Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares in the last quarter. AustralianSuper Pty Ltd increased its position in Johnson & Johnson by 632.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after buying an additional 77,000 shares in the last quarter. J.W. Cole Advisors Inc. boosted its holdings in Johnson & Johnson by 2.2% in the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after acquiring an additional 2,769 shares in the last quarter. Guinness Asset Management LTD boosted its holdings in Johnson & Johnson by 0.4% in the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock worth $251,216,000 after acquiring an additional 5,994 shares in the last quarter. Finally, Treasurer of the State of North Carolina grew its stake in shares of Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after acquiring an additional 94,957 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on JNJ. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Guggenheim raised their price target on shares of Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Citigroup raised their target price on Johnson & Johnson from $232.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $232.70.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Momentum from product mix and earnings beat: Recent coverage highlights a “triple threat” for JNJ — stronger oncology sales, a MedTech rebound, and a surprise earnings beat that beat tariff headwinds, supporting continued upside potential. Does JNJ Stock Still Offer Value?
• Positive Sentiment: Potential asset sale of DePuy Synthes could unlock value: Bloomberg reports J&J is exploring a possible sale of its orthopedics unit as part of separation plans — a divestiture could raise cash, simplify the company and be viewed as value-accretive by investors. Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)
• Positive Sentiment: Ongoing retail and dividend-focused bullishness reinforces investor demand: Multiple retail-focused pieces (The Motley Fool, Yahoo) continue to paint JNJ as a core, low-volatility dividend holding, supporting sustained buying interest from income and long-term investors. The Only Healthcare Stock I’d Buy and Never Sell Might Be Johnson & Johnson
• Neutral Sentiment: Strategic partnership/co-funding with Blackstone noted but short-term impact unclear: J&J announced a first co-funding agreement with Blackstone; strategic but the market reaction has been muted and concrete near-term benefits remain to be proven. Johnson & Johnson (JNJ) Stock Flat despite First Co-funding Agreement with Blackstone
• Neutral Sentiment: Options activity and analyst notes mixed: Unusually high options trading and a raised but modest price-target move have created noise rather than a clear directional signal. Johnson & Johnson Target of Unusually High Options Trading (NYSE:JNJ) Johnson & Johnson (NYSE:JNJ) Price Target Raised to $210.00
• Negative Sentiment: Bayer lawsuit creates legal overhang: Bayer filed a New York lawsuit against J&J and Janssen over prostate cancer drug Nubeqa — adds litigation risk and potential distraction for the biotech unit. Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
• Negative Sentiment: Insider sale disclosed: EVP Timothy Schmid sold 1,322 shares (filed Form 4), trimming his stake — routine but can be viewed negatively by some investors as a signal to take profits. SEC filing: Form 4

Johnson & Johnson Trading Up 1.3%

Shares of NYSE:JNJ opened at $245.53 on Tuesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $246.96. The business has a 50 day moving average of $221.69 and a two-hundred day moving average of $199.96. The company has a market capitalization of $591.70 billion, a PE ratio of 22.22, a PEG ratio of 2.35 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 47.06%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 30,142 shares of company stock worth $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.